Asset profile

OLN324 · Johnson & Johnson (JNJ)

Indication
retinal vascular diseases including wet age-related macular degeneration (AMD) and diabetic macular edema
CompanyJNJJohnson & Johnson

Johnson & Johnson is the world's largest and most diverse healthcare firm. It has two divisions: innovative medicine and medtech. These now represent all of the company's sales following the divestment of the consumer business, Kenvue, in 2023. After restructu…

Registered trials

Registry IDPhaseStatusPrimary completionEnrollmentSites
NCT07816315Phase 3Not yet recruitingDec 15, 2028500
NCT07841899Phase 3Not yet recruitingDec 15, 2028450
NCT07816289Phase 3Not yet recruitingDec 15, 2028400
NCT07842016Phase 3Not yet recruitingDec 15, 2028450

More from Johnson & Johnson

Other drugs and candidates from the same company tracked in this sector.

OLN324 · Johnson & Johnson (JNJ) — FDA Timeline & Readiness Checklist | SimianX AI